Accuray Incorporated (Nasdaq ARAY), a global leader in the field of radiosurgery, announced today that the company will showcase the treatment planning capabilities of the CyberKnife(R) Robotic Radiosurgery System at the 10th Biennial European Society for Therapeutic Radiology and Oncology (ESTRO) Conference on Physics and Radiation Technology for Clinical Radiotherapy in Maastricht, The Netherlands.

The latest generation of the MultiPlan(R) Treatment Planning System provides the most comprehensive set of tools available for highprecision radiosurgery treatment planning. The CyberKnife Systems planning capabilities also include Monte Carlo Dose Calculation, which produces results in minutes compared to what commonly requires hours or days with other systems.

“We strongly believe that these new capabilities will transform the treatment planning practice, specifically for the treatment of lung tumors,” said Frederic Sottilini, Senior Director, Marketing, Accuray EMEA.

Clinical findings will be presented during the conference, including the results of a study presented by Erasmus MCDaniel den Hoed Cancer Center that demonstrates the benefits of the dose calculations performed using the CyberKnife Systems Monte Carlo Dose Calculation in the treatment of NonSmall Cell Lung Cancer.

Additionally a Lunch Symposium will be held on Monday, August 31 at 100 p.m. CET in room 04/05, where conference attendees can learn more about the versatility and precision of the CyberKnife Systems treatment planning and delivery technologies.

“Medical physicists from renowned academic centers will contribute to the scientific quality of this symposium, which should gather physicists from all over Europe who are interested in learning more about the highlysophisticated treatment planning techniques that are available,” said Sottilini.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the worlds only robotic radiosurgery system designed to treat tumors anywhere in the body noninvasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in realtime throughout the treatment. This enables the CyberKnife System to deliver highdose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a nonsurgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 176 systems have been installed in leading hospitals in the Americas, Europe and Asia.

Safe Harbor Statement

The foregoing may contain certain forwardlooking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, as to performance of products, clinical studies, and market acceptance are forwardlooking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or managements good faith belief as of that time with respect to future events. You should not put undue reliance on any forwardlooking statements. Important factors that could cause actual performance and results to differ materially from the forwardlooking statements we make include commercialization of products; market acceptance of products; competing products; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10K for the 2008 fiscal year, as updated from time to time by our quarterly reports on Form 10Q and our other filings with the Securities and Exchange Commission. The Companys actual results of operations may differ significantly from those contemplated by such forwardlooking statements as a result of these and other factors. We assume no obligation to update forwardlooking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forwardlooking information, except to the extent required by applicable securities laws.